Company intelligence / Profile preview

Pamlico Pharmaceutical

Oklahoma City, Oklahoma, United States

Ownership: Private
Development stage: Other

Overview

Pamlico has a diverse portfolio of marketed medicines including leading therapies for sleep disorders and epilepsy, with a growing portfolio of cancer treatments. The company's lead monoclonal antibody program focused on severe pneumonia caused by Streptococcus pneumoniae was in IND-enabling studies for a mAb cocktail and companion point-of-care diagnostic.[2]

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Partnerships

Sanovia (SAN2355 exclusive licensing agreement)[4]

Beyond the preview

Go deeper on Pamlico Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pamlico Pharmaceutical.

Explore the full profile